New disease found in drug users: researchers race to understand it
NCT ID NCT06573671
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study looks at a newly identified lung condition called histiocytosis in people who inject drugs. Researchers will study 30 patients to understand symptoms, diagnosis, and outcomes. They will also test new ways to detect a substance called polyvinylpyrrolidone (PVP) that may cause the condition. The goal is to improve diagnosis and distinguish it from other similar diseases.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better diagnose and understand a rare lung condition linked to injecting crushed tablets.
- What could go wrong
- This is a small, early observational study with only 30 participants, so findings may not apply broadly. It aims to describe the condition, not test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients admitting to intravenous use of dissolved tablets (indicated for oral use) containing polyvinylpyrrolidone (PVP30) and positive tissue sample in any tissue biopsy compatible with features of histiocytosis caused by PVP30
- Ages
-
18 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All identified adult patients in our records with a history of injecting drug use by dissolving tablets containing polyvinylpyrrolidone and (suspected) PVP-histiocytosis Exclusion Criteria: * Other histiocytosis diagnosed by tissue samples and clinical information
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Histiocytosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tampere University Hospital
Tampere, Pirkanmaa, 33101, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive study tracks hidden toll of rare immune diseases
- Rare disease study probes hidden brain effects
- New hope for kids with rare blood cancer: targeted drug trial launches
- New hope for kids with rare blood disorder: trametinib trial launches
- New imaging test could spot rare childhood disease sooner
- Promising combo aims to tame relapsed childhood cancers